Preview
Sign-in for full Details 
Sign-in free and Explore the Exciting World of BiomedExperts:
- Over 1.500.000 Profiles
- More than 1.800 Organizations worldwide
- State of the Art Network Visualizations
- Manage your own Profile
- Locate Experts in your Country/Region
- Locate Experts in your 1. and 2. Level Network
- Connect to Experts Worldwide
NetworkView
Robert Kreitman
This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers
together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles
free of charge to researchers worldwide.
Research Profile (preview)
Chemicals & Drugs
Anatomy
Living Beings
Disorders
Concepts & Ideas
Sign-in to see full Profile
Network (preview)
90
Pastan, Ira
20
FitzGerald, David
16
Stetler-Stevenson, Maryalice
10
Nagata, Satoshi
10
Margulies, Inger
10
Puri, Raj
9
Onda, Masanori
9
Hassan, Raffit
6
Lee, Byungkook
6
Leland, Pamela
6
Rozemuller, Henk
6
Wang, Qing-Cheng
6
Wilson, Wyndham
5
Waldmann, Thomas
5
Martens, Anton
Sign-in to see all Coauthors
Publications
Sign-in to see all Publications
Sign in free and see...
Visualized networks:
See your personal network in
sophisticated graphical views
GeoTargeted Searches:
Locate experts around the world
and connect with global collaborators
Research Profiles:
See the visualized research activity
of experts around the globe
Sign-in to see more
Geonetwork of Robert Kreitman (preview)
Cities where this author has publications
Cities where co-authors of this author have publications
Sign-in to see more
All Publications
-
2009: Kreitman Robert J; Fitzgerald David J P; Pastan Ira
Approach to the patient after relapse of hairy cell leukemia.
Leukemia & lymphoma 2009;50 Suppl 1():32-7.
-
2009: Kreitman Robert J; Hassan Raffit; Fitzgerald David J; Pastan Ira
Phase I trial of continuous infusion anti-mesothelin recombinant immunotoxin SS1P.
Clinical cancer research : an official journal of the American Association for Cancer Research 2009;15(16):5274-9.
-
2009: Kreitman Robert J; Stetler-Stevenson Maryalice; Margulies Inger; Noel Pierre; Fitzgerald David J P; Wilson Wyndham H; Pastan Ira
Phase II trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with hairy cell leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(18):2983-90.
-
2009: Weldon John E; Xiang Laiman; Chertov Oleg; Margulies Inger; Kreitman Robert J; FitzGerald David J; Pastan Ira
A protease-resistant immunotoxin against CD22 with greatly increased activity against CLL and diminished animal toxicity.
Blood 2009;113(16):3792-800.
-
2009: Kreitman Robert J
Recombinant immunotoxins for the treatment of chemoresistant hematologic malignancies.
Current pharmaceutical design 2009;15(23):2652-64.
-
2009: Kreitman Robert J
Recombinant immunotoxins containing truncated bacterial toxins for the treatment of hematologic malignancies.
BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy 2009;23(1):1-13.
-
2008: Matsushita Kakushi; Margulies Inger; Onda Masanori; Nagata Satoshi; Stetler-Stevenson Maryalice; Kreitman Robert J
Soluble CD22 as a tumor marker for hairy cell leukemia.
Blood 2008;112(6):2272-7.
-
2008: Arons Evgeny; Suntum Tara; Margulies Inger; Yuan Constance; Stetler-Stevenson Maryalice; Kreitman Robert J
PRAME expression in hairy cell leukemia.
Leukemia research 2008;32(9):1400-6.
-
2008: Ahmad Ejaz; Steinberg Seth M; Goldin Lynn; Hess Christopher J; Caporaso Neil; Kreitman Robert J; Wiestner Adrian; Wilson Wyndham; White Therese; Marti Gerald; Stetler-Stevenson Maryalice
Immunophenotypic features distinguishing familial chronic lymphocytic leukemia from sporadic chronic lymphocytic leukemia.
Cytometry. Part B, Clinical cytometry 2008;74(4):221-6.
-
2007: Powell Daniel J; Felipe-Silva Aloisio; Merino Maria J; Ahmadzadeh Mojgan; Allen Tamika; Levy Catherine; White Donald E; Mavroukakis Sharon; Kreitman Robert J; Rosenberg Steven A; Pastan Ira
Administration of a CD25-directed immunotoxin, LMB-2, to patients with metastatic melanoma induces a selective partial reduction in regulatory T cells in vivo.
Journal of immunology (Baltimore, Md. : 1950) 2007;179(7):4919-28.
-
2007: Hassan Raffit; Bullock Susie; Premkumar Ahalya; Kreitman Robert J; Kindler Hedy; Willingham Mark C; Pastan Ira
Phase I study of SS1P, a recombinant anti-mesothelin immunotoxin given as a bolus I.V. infusion to patients with mesothelin-expressing mesothelioma, ovarian, and pancreatic cancers.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(17):5144-9.
-
2007: Arons Evgeny; Suntum Tara; Sunshine Joel; Stetler-Stevenson Maryalice; Kreitman Robert J
Immunoglobulin light chain repertoire in hairy cell leukemia.
Leukemia research 2007;31(9):1231-6.
-
2007: Filpula David; Yang Karen; Basu Amartya; Hassan Raffit; Xiang Laiman; Zhang Zhenfan; Wang Maoliang; Wang Qing-cheng; Ho Mitchell; Beers Richard; Zhao Hong; Peng Ping; Zhou John; Li Xiguang; Petti Gerald; Janjua Ahsen; Liu Jun; Wu Dechun; Yu Deshan; Zhang Zhihua; Longley Clifford; FitzGerald David; Kreitman Robert J; Pastan Ira
Releasable PEGylation of mesothelin targeted immunotoxin SS1P achieves single dosage complete regression of a human carcinoma in mice.
Bioconjugate chemistry 2007;18(3):773-84.
-
2007: Ise T; Nagata S; Kreitman R J; Wilson W H; Wayne A S; Stetler-Stevenson M; Bishop M R; Scheinberg D A; Rassenti L; Kipps T J; Kyle R A; Jelinek D F; Pastan I
Elevation of soluble CD307 (IRTA2/FcRH5) protein in the blood and expression on malignant cells of patients with multiple myeloma, chronic lymphocytic leukemia, and mantle cell lymphoma.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2007;21(1):169-74.
-
2007: Pastan Ira; Hassan Raffit; FitzGerald David J; Kreitman Robert J
Immunotoxin treatment of cancer.
Annual review of medicine 2007;58():221-37.
-
2006: Onda Masanori; Nagata Satoshi; FitzGerald David J; Beers Richard; Fisher Robert J; Vincent James J; Lee Byungkook; Nakamura Michihiro; Hwang Jaulang; Kreitman Robert J; Hassan Raffit; Pastan Ira
Characterization of the B cell epitopes associated with a truncated form of Pseudomonas exotoxin (PE38) used to make immunotoxins for the treatment of cancer patients.
Journal of immunology (Baltimore, Md. : 1950) 2006;177(12):8822-34.
-
2006: Kreitman Robert J; Pastan Ira
Immunotoxins in the treatment of hematologic malignancies.
Current drug targets 2006;7(10):1301-11.
-
2006: Kreitman Robert J; Pastan Ira
Immunotoxins in the treatment of refractory hairy cell leukemia.
Hematology/oncology clinics of North America 2006;20(5):1137-51, viii.
-
2006: Arons Evgeny; Sorbara Lynn; Raffeld Mark; Stetler-Stevenson Maryalice; Steinberg Seth M; Liewehr David J; Pastan Ira; Kreitman Robert J
Characterization of T-cell repertoire in hairy cell leukemia patients before and after recombinant immunotoxin BL22 therapy.
Cancer immunology, immunotherapy : CII 2006;55(9):1100-10.
-
2006: Pastan Ira; Hassan Raffit; Fitzgerald David J; Kreitman Robert J
Immunotoxin therapy of cancer.
Nature reviews. Cancer 2006;6(7):559-65.
-
2006: Kimchi-Sarfaty C; Vieira W D; Dodds D; Sherman A; Kreitman R J; Shinar S; Gottesman M M
SV40 Pseudovirion gene delivery of a toxin to treat human adenocarcinomas in mice.
Cancer gene therapy 2006;13(7):648-57.
-
2006: Arons Evgeny; Sunshine Joel; Suntum Tara; Kreitman Robert J
Somatic hypermutation and VH gene usage in hairy cell leukaemia.
British journal of haematology 2006;133(5):504-12.
-
2006: Arons Evgeny; Margulies Inger; Sorbara Lynn; Raffeld Mark; Stetler-Stevenson Maryalice; Pastan Ira; Kreitman Robert J
Minimal residual disease in hairy cell leukemia patients assessed by clone-specific polymerase chain reaction.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(9):2804-11.
-
2006: Attia Peter; Powell Daniel J; Maker Ajay V; Kreitman Robert J; Pastan Ira; Rosenberg Steven A
Selective elimination of human regulatory T lymphocytes in vitro with the recombinant immunotoxin LMB-2.
Journal of immunotherapy (Hagerstown, Md. : 1997) 2006;29(2):208-14.
-
2006: Kreitman Robert J
Immunotoxins for targeted cancer therapy.
The AAPS journal 2006;8(3):E532-51.
-
2006: Kreitman Robert J; Pastan Ira
BL22 and lymphoid malignancies.
Best practice & research. Clinical haematology 2006;19(4):685-99.
-
2006: Ise Tomoko; Kreitman Robert J; Pastan Ira; Nagata Satoshi
Sandwich ELISAs for soluble immunoglobulin superfamily receptor translocation-associated 2 (IRTA2)/FcRH5 (CD307) proteins in human sera.
Clinical chemistry and laboratory medicine : CCLM / FESCC 2006;44(5):594-602.
-
2005: Hassan Raffit; Kreitman Robert J; Pastan Ira; Willingham Mark C
Localization of mesothelin in epithelial ovarian cancer.
Applied immunohistochemistry & molecular morphology : AIMM / official publication of the Society for Applied Immunohistochemistry 2005;13(3):243-7.
-
2005: Kreitman Robert J; Squires David R; Stetler-Stevenson Maryalice; Noel Pierre; FitzGerald David J P; Wilson Wyndham H; Pastan Ira
Phase I trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with B-cell malignancies.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(27):6719-29.
-
2005: Onda Masanori; Willingham Mark; Nagata Satoshi; Bera Tapan K; Beers Richard; Ho Mitchell; Hassan Raffit; Kreitman Robert J; Pastan Ira
New monoclonal antibodies to mesothelin useful for immunohistochemistry, fluorescence-activated cell sorting, Western blotting, and ELISA.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(16):5840-6.
-
2005: Bang Sookhee; Nagata Satoshi; Onda Masanori; Kreitman Robert J; Pastan Ira
HA22 (R490A) is a recombinant immunotoxin with increased antitumor activity without an increase in animal toxicity.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(4):1545-50.
-
2005: Ise Tomoko; Maeda Hiroshi; Santora Kenneth; Xiang Laiman; Kreitman Robert J; Pastan Ira; Nagata Satoshi
Immunoglobulin superfamily receptor translocation associated 2 protein on lymphoma cell lines and hairy cell leukemia cells detected by novel monoclonal antibodies.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(1):87-96.
-
2005: Ho Mitchell; Kreitman Robert J; Onda Masanori; Pastan Ira
In vitro antibody evolution targeting germline hot spots to increase activity of an anti-CD22 immunotoxin.
The Journal of biological chemistry 2005;280(1):607-17.
-
2004: Kreitman Robert J
Confirmation and prevention of targeted toxicity by a recombinant fusion toxin.
Molecular cancer therapeutics 2004;3(12):1691-2.
-
2004: Kreitman Robert J
Recombinant immunotoxins for the treatment of haematological malignancies.
Expert opinion on biological therapy 2004;4(7):1115-28.
-
2004: Decker Thomas; Oelsner Madlene; Kreitman Robert J; Salvatore Giuliana; Wang Qing-cheng; Pastan Ira; Peschel Christian; Licht Thomas
Induction of caspase-dependent programmed cell death in B-cell chronic lymphocytic leukemia by anti-CD22 immunotoxins.
Blood 2004;103(7):2718-26.
-
2003: Kreitman Robert J; Pastan Ira
Immunobiological treatments of hairy-cell leukaemia.
Best practice & research. Clinical haematology 2003;16(1):117-33.
-
2003: Sausville Justin E; Salloum Rita G; Sorbara Lynn; Kingma Douglas W; Raffeld Mark; Kreitman Robert J; Imus Paula D; Venzon David; Stetler-Stevenson Maryalice
Minimal residual disease detection in hairy cell leukemia. Comparison of flow cytometric immunophenotyping with clonal analysis using consensus primer polymerase chain reaction for the heavy chain gene.
American journal of clinical pathology 2003;119(2):213-7.
-
2002: Kreitman Robert J
Recombinant fusion toxins for cancer treatment.
Expert opinion on biological therapy 2002;2(8):785-91.
-
2002: Pastan Ira; Kreitman Robert J
Immunotoxins in cancer therapy.
Current opinion in investigational drugs (London, England : 2000) 2002;3(7):1089-91.
-
2002: Nagata Satoshi; Onda Masanori; Numata Yoshito; Santora Kenneth; Beers Richard; Kreitman Robert J; Pastan Ira
Novel anti-CD30 recombinant immunotoxins containing disulfide-stabilized Fv fragments.
Clinical cancer research : an official journal of the American Association for Cancer Research 2002;8(7):2345-55.
-
2002: Salvatore Giuliana; Beers Richard; Margulies Inger; Kreitman Robert J; Pastan Ira
Improved cytotoxic activity toward cell lines and fresh leukemia cells of a mutant anti-CD22 immunotoxin obtained by antibody phage display.
Clinical cancer research : an official journal of the American Association for Cancer Research 2002;8(4):995-1002.
-
2001: Kreitman R J
Toxin-labeled monoclonal antibodies.
Current pharmaceutical biotechnology 2001;2(4):313-25.
-
2001: Kreitman R J
Chimeric fusion proteins--Pseudomonas exotoxin-based.
Current opinion in investigational drugs (London, England : 2000) 2001;2(9):1282-93.
-
2001: Kreitman R J; Wilson W H; Bergeron K; Raggio M; Stetler-Stevenson M; FitzGerald D J; Pastan I
Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia.
The New England journal of medicine 2001;345(4):241-7.
-
2001: Onda M; Nagata S; Tsutsumi Y; Vincent J J; Wang Q; Kreitman R J; Lee B; Pastan I
Lowering the isoelectric point of the Fv portion of recombinant immunotoxins leads to decreased nonspecific animal toxicity without affecting antitumor activity.
Cancer research 2001;61(13):5070-7.
-
2001: Rozemuller H; Chowdhury P S; Pastan I; Kreitman R J
Isolation of new anti-CD30 scFvs from DNA-immunized mice by phage display and biologic activity of recombinant immunotoxins produced by fusion with truncated pseudomonas exotoxin.
International journal of cancer. Journal international du cancer 2001;92(6):861-70.
-
2001: Kreitman R J
Quantification of immunotoxin number for complete therapeutic response.
Methods in molecular biology (Clifton, N.J.) 2001;166():111-23.
-
2000: Onda M; Willingham M; Wang Q C; Kreitman R J; Tsutsumi Y; Nagata S; Pastan I
Inhibition of TNF-alpha produced by Kupffer cells protects against the nonspecific liver toxicity of immunotoxin anti-Tac(Fv)-PE38, LMB-2.
Journal of immunology (Baltimore, Md. : 1950) 2000;165(12):7150-6.
-
2000: Kreitman R J
Immunotoxins.
Expert opinion on pharmacotherapy 2000;1(6):1117-29.
-
2000: Hassan R; Viner J L; Wang Q C; Margulies I; Kreitman R J; Pastan I
Anti-tumor activity of K1-LysPE38QQR, an immunotoxin targeting mesothelin, a cell-surface antigen overexpressed in ovarian cancer and malignant mesothelioma.
Journal of immunotherapy (Hagerstown, Md. : 1997) 2000;23(4):473-9.
-
2000: Tsutsumi Y; Onda M; Nagata S; Lee B; Kreitman R J; Pastan I
Site-specific chemical modification with polyethylene glycol of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) improves antitumor activity and reduces animal toxicity and immunogenicity.
Proceedings of the National Academy of Sciences of the United States of America 2000;97(15):8548-53.
-
2000: Keppler-Hafkemeyer A; Kreitman R J; Pastan I
Apoptosis induced by immunotoxins used in the treatment of hematologic malignancies.
International journal of cancer. Journal international du cancer 2000;87(1):86-94.
-
2000: Kreitman R J; Margulies I; Stetler-Stevenson M; Wang Q C; FitzGerald D J; Pastan I
Cytotoxic activity of disulfide-stabilized recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) toward fresh malignant cells from patients with B-cell leukemias.
Clinical cancer research : an official journal of the American Association for Cancer Research 2000;6(4):1476-87.
-
2000: Kobayashi H; Kao C H; Kreitman R J; Le N; Kim M K; Brechbiel M W; Paik C H; Pastan I; Carrasquillo J A
Pharmacokinetics of 111In- and 125I-labeled antiTac single-chain Fv recombinant immunotoxin.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2000;41(4):755-62.
-
2000: Kreitman R J; Wilson W H; White J D; Stetler-Stevenson M; Jaffe E S; Giardina S; Waldmann T A; Pastan I
Phase I trial of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) in patients with hematologic malignancies.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000;18(8):1622-36.
-
2000: Xie X Y; Sorbara L; Kreitman R J; Fukushima P I; Kingma D W; Stetler-Stevenson M
Development of lymphoproliferative disorder of granular lymphocytes in association with hairy cell leukemia.
Leukemia & lymphoma 2000;37(1-2):97-104.
-
2000: Rajagopal V; Kreitman R J
Recombinant toxins that bind to the urokinase receptor are cytotoxic without requiring binding to the alpha(2)-macroglobulin receptor.
The Journal of biological chemistry 2000;275(11):7566-73.
-
2000: Robbins D H; Margulies I; Stetler-Stevenson M; Kreitman R J
Hairy cell leukemia, a B-cell neoplasm that is particularly sensitive to the cytotoxic effect of anti-Tac(Fv)-PE38 (LMB-2).
Clinical cancer research : an official journal of the American Association for Cancer Research 2000;6(2):693-700.
-
1999: Onda M; Kreitman R J; Vasmatzis G; Lee B; Pastan I
Reduction of the nonspecific animal toxicity of anti-Tac(Fv)-PE38 by mutations in the framework regions of the Fv which lower the isoelectric point.
Journal of immunology (Baltimore, Md. : 1950) 1999;163(11):6072-7.
-
1999: Kreitman R J; Wilson W H; Robbins D; Margulies I; Stetler-Stevenson M; Waldmann T A; Pastan I
Responses in refractory hairy cell leukemia to a recombinant immunotoxin.
Blood 1999;94(10):3340-8.
-
1999: Kreitman R J
Immunotoxins in cancer therapy.
Current opinion in immunology 1999;11(5):570-8.
-
1999: Jwang B; Yerushalmi N; Kreitman R J; Engberg J; Pastan I
An scFv phage clone that binds to human beta2-microglobulin.
Immunotechnology : an international journal of immunological engineering 1999;4(3-4):231-6.
-
1999: Kreitman R J; Wang Q C; FitzGerald D J; Pastan I
Complete regression of human B-cell lymphoma xenografts in mice treated with recombinant anti-CD22 immunotoxin RFB4(dsFv)-PE38 at doses tolerated by cynomolgus monkeys.
International journal of cancer. Journal international du cancer 1999;81(1):148-55.
-
1999: Hassan R; Wu C; Brechbiel M W; Margulies I; Kreitman R J; Pastan I
111Indium-labeled monoclonal antibody K1: biodistribution study in nude mice bearing a human carcinoma xenograft expressing mesothelin.
International journal of cancer. Journal international du cancer 1999;80(4):559-63.
-
1998: Rozemuller H; Terpstra W; Rombouts E J; Lawler M; Byrne C; FitzGerald D J; Kreitman R J; Wielenga J J; Löwenberg B; Touw I P; Hagenbeek A; Martens A C
GM-CSF receptor targeted treatment of primary AML in SCID mice using Diphtheria toxin fused to huGM-CSF.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1998;12(12):1962-70.
-
1998: Kobayashi H; Han E S; Kim I S; Le N; Rajagopal V; Kreitman R J; Pastan I; Paik C H; Carrasquillo J A
Similarities in the biodistribution of iodine-labeled anti-Tac single-chain disulfide-stabilized Fv fragment and anti-Tac disulfide-stabilized Fv fragment.
Nuclear medicine and biology 1998;25(4):387-93.
-
1998: Rozemuller H; Rombouts E J; Touw I P; FitzGerald D J; Kreitman R J; Hagenbeek A; Martens A C
In vivo targeting of leukemic cells using diphtheria toxin fused to murine GM-CSF.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1998;12(5):710-7.
-
1998: Kreitman R J; Pastan I
Accumulation of a recombinant immunotoxin in a tumor in vivo: fewer than 1000 molecules per cell are sufficient for complete responses.
Cancer research 1998;58(5):968-75.
-
1997: Rajagopal V; Pastan I; Kreitman R J
A form of anti-Tac(Fv) which is both single-chain and disulfide stabilized: comparison with its single-chain and disulfide-stabilized homologs.
Protein engineering 1997;10(12):1453-9.
-
1997: Hessler J L; Kreitman R J
An early step in Pseudomonas exotoxin action is removal of the terminal lysine residue, which allows binding to the KDEL receptor.
Biochemistry 1997;36(47):14577-82.
-
1997: Terpstra W; Rozemuller H; Breems D A; Rombouts E J; Prins A; FitzGerald D J; Kreitman R J; Wielenga J J; Ploemacher R E; Löwenberg B; Hagenbeek A; Martens A C
Diphtheria toxin fused to granulocyte-macrophage colony-stimulating factor eliminates acute myeloid leukemia cells with the potential to initiate leukemia in immunodeficient mice, but spares normal hemopoietic stem cells.
Blood 1997;90(9):3735-42.
-
1997: Kreitman R J
Getting plant toxins to fuse.
Leukemia research 1997;21(10):997-9.
-
1997: Rozemuller H; Rombouts E J; Touw I P; FitzGerald D J; Kreitman R J; Pastan I; Hagenbeek A; Martens A C
Sensitivity of human acute myeloid leukaemia to diphtheria toxin-GM-CSF fusion protein.
British journal of haematology 1997;98(4):952-9.
-
1997: Kreitman R J; Pastan I
Recombinant toxins containing human granulocyte-macrophage colony-stimulating factor and either pseudomonas exotoxin or diphtheria toxin kill gastrointestinal cancer and leukemia cells.
Blood 1997;90(1):252-9.
-
1996: Puri R K; Hoon D S; Leland P; Snoy P; Rand R W; Pastan I; Kreitman R J
Preclinical development of a recombinant toxin containing circularly permuted interleukin 4 and truncated Pseudomonas exotoxin for therapy of malignant astrocytoma.
Cancer research 1996;56(24):5631-7.
-
1996: Rozemuller H; Rombouts W J; Touw I P; FitzGerald D J; Kreitman R J; Pastan I; Hagenbeek A; Martens A C
Treatment of acute myelocytic leukemia with interleukin-6 Pseudomonas exotoxin fusion protein in a rat leukemia model.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1996;10(11):1796-803.
-
1996: Puri R K; Leland P; Obiri N I; Husain S R; Mule J; Pastan I; Kreitman R J
An improved circularly permuted interleukin 4-toxin is highly cytotoxic to human renal cell carcinoma cells. Introduction of gamma c chain in RCC cells does not improve sensitivity.
Cellular immunology 1996;171(1):80-6.
-
1996: Mavroudis D A; Jiang Y Z; Hensel N; Lewalle P; Couriel D; Kreitman R J; Pastan I; Barrett A J
Specific depletion of alloreactivity against haplotype mismatched related individuals by a recombinant immunotoxin: a new approach to graft-versus-host disease prophylaxis in haploidentical bone marrow transplantation.
Bone marrow transplantation 1996;17(5):793-9.
-
1996: Puri R K; Leland P; Obiri N I; Husain S R; Kreitman R J; Haas G P; Pastan I; Debinski W
Targeting of interleukin-13 receptor on human renal cell carcinoma cells by a recombinant chimeric protein composed of interleukin-13 and a truncated form of Pseudomonas exotoxin A (PE38QQR).
Blood 1996;87(10):4333-9.
-
1995: Kreitman R J; Pastan I
Targeting Pseudomonas exotoxin to hematologic malignancies.
Seminars in cancer biology 1995;6(5):297-306.
-
1995: Kreitman R J; Puri R K; Pastan I
Increased antitumor activity of a circularly permuted interleukin 4-toxin in mice with interleukin 4 receptor-bearing human carcinoma.
Cancer research 1995;55(15):3357-63.
-
1995: Kreitman R J; Puri R K; McPhie P; Pastan I
Circularly permuted interleukin 4 retains proliferative and binding activity.
Cytokine 1995;7(4):311-8.
-
1995: Kreitman R J; Pastan I
Importance of the glutamate residue of KDEL in increasing the cytotoxicity of Pseudomonas exotoxin derivatives and for increased binding to the KDEL receptor.
The Biochemical journal 1995;307 ( Pt 1)():29-37.
-
1995: Webber K O; Reiter Y; Brinkmann U; Kreitman R; Pastan I
Preparation and characterization of a disulfide-stabilized Fv fragment of the anti-Tac antibody: comparison with its single-chain analog.
Molecular immunology 1995;32(4):249-58.
-
1995: Webber K O; Kreitman R J; Pastan I
Rapid and specific uptake of anti-Tac disulfide-stabilized Fv by interleukin-2 receptor-bearing tumors.
Cancer research 1995;55(2):318-23.
-
1994: Kreitman R J; Puri R K; Leland P; Lee B; Pastan I
Site-specific conjugation to interleukin 4 containing mutated cysteine residues produces interleukin 4-toxin conjugates with improved binding and activity.
Biochemistry 1994;33(38):11637-44.
-
1994: Mesri E A; Ono M; Kreitman R J; Klagsbrun M; Pastan I
The heparin-binding domain of heparin-binding EGF-like growth factor can target Pseudomonas exotoxin to kill cells exclusively through heparan sulfate proteoglycans.
Journal of cell science 1994;107 ( Pt 9)():2599-608.
-
1994: Puri R K; Leland P; Kreitman R J; Pastan I
Human neurological cancer cells express interleukin-4 (IL-4) receptors which are targets for the toxic effects of IL4-Pseudomonas exotoxin chimeric protein.
International journal of cancer. Journal international du cancer 1994;58(4):574-81.
-
1994: Kreitman R J; Puri R K; Pastan I
A circularly permuted recombinant interleukin 4 toxin with increased activity.
Proceedings of the National Academy of Sciences of the United States of America 1994;91(15):6889-93.
-
1994: Reiter Y; Kreitman R J; Brinkmann U; Pastan I
Cytotoxic and antitumor activity of a recombinant immunotoxin composed of disulfide-stabilized anti-Tac Fv fragment and truncated Pseudomonas exotoxin.
International journal of cancer. Journal international du cancer 1994;58(1):142-9.
-
1994: Kreitman R J; Chang C N; Hudson D V; Queen C; Bailon P; Pastan I
Anti-Tac(Fab)-PE40, a recombinant double-chain immunotoxin which kills interleukin-2-receptor-bearing cells and induces complete remission in an in vivo tumor model.
International journal of cancer. Journal international du cancer 1994;57(6):856-64.
-
1994: Reiter Y; Brinkmann U; Kreitman R J; Jung S H; Lee B; Pastan I
Stabilization of the Fv fragments in recombinant immunotoxins by disulfide bonds engineered into conserved framework regions.
Biochemistry 1994;33(18):5451-9.
-
1994: Puri R K; Mehrotra P T; Leland P; Kreitman R J; Siegel J P; Pastan I
A chimeric protein comprised of IL-4 and Pseudomonas exotoxin is cytotoxic for activated human lymphocytes.
Journal of immunology (Baltimore, Md. : 1950) 1994;152(7):3693-700.
-
1994: Puri R K; Debinski W; Obiri N; Kreitman R; Pastan I
Human renal cell carcinoma cells are sensitive to the cytotoxic effect of a chimeric protein composed of human interleukin-4 and Pseudomonas exotoxin.
Cellular immunology 1994;154(1):369-79.
-
1994: Kreitman R J; Pastan I
Recombinant single-chain immunotoxins against T and B cell leukemias.
Leukemia & lymphoma 1994;13(1-2):1-10.
-
1994: Kreitman R J; Bailon P; Chaudhary V K; FitzGerald D J; Pastan I
Recombinant immunotoxins containing anti-Tac(Fv) and derivatives of Pseudomonas exotoxin produce complete regression in mice of an interleukin-2 receptor-expressing human carcinoma.
Blood 1994;83(2):426-34.
-
1994: Kreitman R J; Pastan I
Recombinant toxins.
Advances in pharmacology (San Diego, Calif.) 1994;28():193-219.
-
1993: Kreitman R J; Pastan I
Purification and characterization of IL6-PE4E, a recombinant fusion of interleukin 6 with Pseudomonas exotoxin.
Bioconjugate chemistry 1993;4(6):581-5.
-
1993: Fu Y M; Mesri E A; Yu Z X; Kreitman R J; Pastan I; Epstein S E
Cytotoxic effects of vascular smooth muscle cells of the chimeric toxin, heparin binding TGF alpha-Pseudomonas exotoxin.
Cardiovascular research 1993;27(9):1691-7.
-
1993: Debinski W; Puri R K; Kreitman R J; Pastan I
A wide range of human cancers express interleukin 4 (IL4) receptors that can be targeted with chimeric toxin composed of IL4 and Pseudomonas exotoxin.
The Journal of biological chemistry 1993;268(19):14065-70.
-
1993: Kreitman R J; Chaudhary V K; Waldmann T A; Hanchard B; Cranston B; FitzGerald D J; Pastan I
Cytotoxic activities of recombinant immunotoxins composed of Pseudomonas toxin or diphtheria toxin toward lymphocytes from patients with adult T-cell leukemia.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1993;7(4):553-62.
-
1993: Mesri E A; Kreitman R J; Fu Y M; Epstein S E; Pastan I
Heparin-binding transforming growth factor alpha-Pseudomonas exotoxin A. A heparan sulfate-modulated recombinant toxin cytotoxic to cancer cells and proliferating smooth muscle cells.
The Journal of biological chemistry 1993;268(7):4853-62.
-
1993: Kreitman R J; Batra J K; Seetharam S; Chaudhary V K; FitzGerald D J; Pastan I
Single-chain immunotoxin fusions between anti-Tac and Pseudomonas exotoxin: relative importance of the two toxin disulfide bonds.
Bioconjugate chemistry 1993;4(2):112-20.
-
1993: Kreitman R J; Hansen H J; Jones A L; FitzGerald D J; Goldenberg D M; Pastan I
Pseudomonas exotoxin-based immunotoxins containing the antibody LL2 or LL2-Fab' induce regression of subcutaneous human B-cell lymphoma in mice.
Cancer research 1993;53(4):819-25.
-
1993: Spence C; Nachman M; Gately M K; Kreitman R J; Pastan I; Bailon P
Affinity purification and characterization of anti-Tac(Fv)-C3-PE38KDEL: A highly potent cytotoxic agent specific to cells bearing IL-2 receptors.
Bioconjugate chemistry 1993;4(1):63-8.
-
1993: Theuer C P; Kreitman R J; FitzGerald D J; Pastan I
Immunotoxins made with a recombinant form of Pseudomonas exotoxin A that do not require proteolysis for activity.
Cancer research 1993;53(2):340-7.
-
1992: Kreitman R J; Chaudhary V K; Kozak R W; FitzGerald D J; Waldman T A; Pastan I
Recombinant toxins containing the variable domains of the anti-Tac monoclonal antibody to the interleukin-2 receptor kill malignant cells from patients with chronic lymphocytic leukemia.
Blood 1992;80(9):2344-52.
-
1992: Kreitman R J; Schneider W P; Queen C; Tsudo M; Fitzgerald D J; Waldmann T A; Pastan I
Mik-beta 1(Fv)-PE40, a recombinant immunotoxin cytotoxic toward cells bearing the beta-chain of the IL-2 receptor.
Journal of immunology (Baltimore, Md. : 1950) 1992;149(8):2810-5.
-
1992: Kreitman R J; Siegall C B; FitzGerald D J; Epstein J; Barlogie B; Pastan I
Interleukin-6 fused to a mutant form of Pseudomonas exotoxin kills malignant cells from patients with multiple myeloma.
Blood 1992;79(7):1775-80.
-
1992: Kreitman R J; FitzGerald D; Pastan I
Targeting growth factor receptors with fusion toxins.
International journal of immunopharmacology 1992;14(3):465-72.
-
1992: Kreitman R J; Siegall C B; Chaudhary V K; FitzGerald D J; Pastan I
Properties of chimeric toxins with two recognition domains: interleukin 6 and transforming growth factor alpha at different locations in Pseudomonas exotoxin.
Bioconjugate chemistry 1992;3(1):63-8.
-
1992: Kreitman R J; Chaudhary V K; Siegall C B; FitzGerald D J; Pastan I
Rational design of a chimeric toxin: an intramolecular location for the insertion of transforming growth factor alpha within Pseudomonas exotoxin as a targeting ligand.
Bioconjugate chemistry 1992;3(1):58-62.
-
1992: FitzGerald D; Chaudhary V K; Kreitman R J; Siegall C B; Pastan I
Generation of chimeric toxins.
Targeted diagnosis and therapy 1992;7():447-62.
-
1991: Siegall C B; Kreitman R J; FitzGerald D J; Pastan I
Antitumor effects of interleukin 6-Pseudomonas exotoxin chimeric molecules against the human hepatocellular carcinoma, PLC/PRF/5 in mice.
Cancer research 1991;51(11):2831-6.
-
1990: Kreitman R J; Chaudhary V K; Waldmann T; Willingham M C; FitzGerald D J; Pastan I
The recombinant immunotoxin anti-Tac(Fv)-Pseudomonas exotoxin 40 is cytotoxic toward peripheral blood malignant cells from patients with adult T-cell leukemia.
Proceedings of the National Academy of Sciences of the United States of America 1990;87(21):8291-5.
Sign-in to see more
